Shamburg News · 8-K filed Oct 13, 2026, 5:35 PM EDT
Biomea Fusion Reports Phase 1 Topline Results for Oral GLP-1 Candidate BMF-650
BMEA · Biomea Fusion, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On October 13, 2026, Biomea Fusion, Inc. hosted a conference call and webcast on topline data from its ongoing Phase 1 GLP-131 trial of BMF-650 and furnished a slide presentation as Exhibit 99.1. The company also issued a press release announcing Phase 1 results for BMF-650, its investigational next-generation oral small molecule GLP-1 receptor agonist, attached as Exhibit 99.2. The presentation reported that in the Phase 1b multiple ascending dose cohort 5, mean weight loss at 400 mg was -1.4, -1.4 and -1.7 kg per week across consecutive weeks, with 6.1% weight reduction at week 4, and that all TEAEs were mild or moderate with no serious TEAEs.
Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-420684.
Written from the filing by Shamburg Markets. Figures are as reported by the company.